We further observed four homozygous deletions each over TP53 (three sarcomas), CDKN2C, and FAT1, and six homozygous deletions each over MAP2K4 (three breast carcinomas) and CDH1 (five lung cancers). This evidence concerns the gene CDKN2C and lung carcinoma.